Welcome and Setting Context

Mr. Sudarshan Jain
Secretary General, Indian Pharmaceutical Alliance
**India Pharma industry contributes significantly to public healthcare globally**

<table>
<thead>
<tr>
<th>India</th>
<th>US</th>
<th>Global</th>
</tr>
</thead>
<tbody>
<tr>
<td>36% lower per person disease burden (DALY, 1990-2016)</td>
<td>~40% Of all drugs consumed in the USA</td>
<td>3rd largest share of drugs by volume</td>
</tr>
<tr>
<td>95% lower treatment costs of life threatening diseases (Hep-C, Leukemia)</td>
<td>395 (42%) Indian ANDA’s approved in 2019 (% of global share)</td>
<td>60% of global vaccine production</td>
</tr>
<tr>
<td>100% eradication of Polio through active collaboration between manufacturers, providers, government, etc.</td>
<td>1st (665) in number of USFDA approved plants outside of US (# of US FDA approved plants in India)</td>
<td>37% of AIDS patients Receiving treatment (in 2009) in Africa, due to greater availability &amp; affordability of Indian drugs</td>
</tr>
</tbody>
</table>

**SOURCE:** IPA report on Indian pharmaceutical industry - the way forward (June 2019); press search, USFDA approval database
IPA Quality Forum formed in 2015 with a vision to help the Indian Pharma industry to achieve quality excellence

IPA QF Mission

1. Be the conduit of change through **thought leadership, knowledge development, and best practice sharing**

2. Expand the **size and base of Quality talent** in India

3. Deepen, and strengthen the industry’s relationship with key stakeholders – both within and outside India

4. Measure, benchmark, and disseminate progress over time

5. Provide platforms for members and other stakeholders to interact and network

The IPA Quality Forum was setup ~5 years back, by a group of 6 founding member companies
In the last 5 years the IPA QF has completed 2 stages of the journey, and is now in the initial years of the third stage.